04:55 AM EDT, 05/24/2024 (MT Newswires) -- Evaxion Biotech ( EVAX ) said late Thursday it plans to present "positive" immune data from a phase 2 study assessing its personalized cancer vaccine EVX-01 combined with anti-PD1 therapy in patients with advanced melanoma.

The company will present the data at an oncology conference in Chicago, Illinois, from May 31 to June 4.

It said the ongoing phase 2 study confirmed findings from the phase 1 trial, reaffirming the ability of its AI-Immunology platform to "precisely select therapeutically relevant vaccine targets."

The data show that the EVX-01 vaccine induced specific and robust immune responses in the phase 2 study. Booster immunizations tended to increase the immune response without imposing any safety concerns. The vaccine was well-tolerated, with only grade 1 and 2 adverse events.

"The immune signatures are both specific and strong, with booster immunizations pointing to further increased immune responses," said Christian Kanstrup, chief executive of Evaxion. "We eagerly await further data readouts on this novel personalized cancer vaccine."